Responding to Targeted Therapies
Dr. Stephen Lessnick: Probably the most important thing actually for targeted therapies is understanding why some patients respond and some patients don't respond. And it's the underlying molecular biology, at least in some cases, that is going to dictate that issue. And so again another key example is that in Gastrointestinal Stromal Tumor, where it's become obvious that certain mutations in the key mutant receptor make it nonresponsive to drugs like Gleevec. And so understanding what that process is is going to allow us then to identify, we hope, new drugs that will target those mutant versions of the receptor, for example. And so that is how we're going to be able to treat everybody effectively, we hope.